{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,5]],"date-time":"2026-05-05T12:23:52Z","timestamp":1777983832255,"version":"3.51.4"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T00:00:00Z","timestamp":1770336000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100000268","name":"RCUK | Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["BB\/W020033\/1"],"award-info":[{"award-number":["BB\/W020033\/1"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000268","name":"RCUK | Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["BB\/X018997\/1"],"award-info":[{"award-number":["BB\/X018997\/1"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000268","name":"RCUK | Biotechnology and Biological Sciences Research Council","doi-asserted-by":"publisher","award":["BB\/X511171\/1"],"award-info":[{"award-number":["BB\/X511171\/1"]}],"id":[{"id":"10.13039\/501100000268","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009187","name":"RCUK | MRC | Medical Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009187","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000833","name":"Rosetrees Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000833","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000265","name":"RCUK | Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Urology Foundation\/John Black Charitable Foundation and Wellcome Institutional Strategic Support Fund"},{"DOI":"10.13039\/501100002341","name":"Academy of Finland","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002341","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9liuksen S\u00e4\u00e4ti\u00f6","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006383","name":"Sy\u00f6p\u00e4j\u00e4rjest\u00f6t","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006383","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002382","name":"King Faisal Specialist Hospital and Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002382","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000771","name":"Prostate Cancer UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000771","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ministry of Science and Education, Republic of Azerbaijan"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Oncogene"],"published-print":{"date-parts":[[2026,3,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Prostate cancer is dependent upon the androgen receptor (AR), the activity of which is modified by cofactors that either enhance or repress its activity, often in a context-dependent manner. FUS\/TLS is a multifunctional protein known to be important in multiple cancer types; in prostate cancer, we previously showed that FUS has a potential tumour suppressor role. Here, transcriptomic analysis of the LNCaP prostate cancer cell line shows a significant overlap in genes regulated by FUS and the androgen receptor. We demonstrate that FUS can regulate androgen receptor activity, in either direction, but predominantly represses androgen signalling. Reporter assays and domain-specific analyses of FUS identified mechanisms by which FUS modifies androgen receptor activity. FUS interacts with the androgen receptor and other cofactors to repress transcription; ChIP assays suggest that repression occurs via disassembly of the transcriptional complex. Quantitative proteomics and RNA-Seq were used to investigate FUS expression in patient samples across prostate cancer stages. FUS was found to be down-regulated in primary tumours, but up-regulated in advanced aggressive stages. These findings suggest that in early prostate cancer, FUS represses AR activity and tumour progression, leading to its down-regulation. In contrast, increased FUS expression in advanced disease appears to be linked to a loss of AR regulatory control.<\/jats:p>","DOI":"10.1038\/s41388-026-03682-3","type":"journal-article","created":{"date-parts":[[2026,2,6]],"date-time":"2026-02-06T05:40:32Z","timestamp":1770356432000},"page":"757-773","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Disruption of androgen receptor-cofactor interactions by the RNA-binding protein FUS\/TLS alters androgen signalling in prostate cancer"],"prefix":"10.1038","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4501-4134","authenticated-orcid":false,"given":"G. N.","family":"Brooke","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3203-9826","authenticated-orcid":false,"given":"D. A.","family":"Leach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R. L.","family":"Culley","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Azadova","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4502-2193","authenticated-orcid":false,"given":"L.","family":"Latonen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"E.","family":"Rees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. A.","family":"Alkheilewi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. C.","family":"Pine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"F. M.","family":"Fioretti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C. S.","family":"Reader","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S. M.","family":"Powell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V.","family":"Reebye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Waxman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Visakorpi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7533-0552","authenticated-orcid":false,"given":"C. L.","family":"Bevan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,2,6]]},"reference":[{"key":"3682_CR1","doi-asserted-by":"publisher","first-page":"18","DOI":"10.2174\/138920209787581307","volume":"10","author":"GN Brooke","year":"2009","unstructured":"Brooke GN, Bevan CL. The role of androgen receptor mutations in prostate cancer progression. Curr Genom. 2009;10:18\u201325.","journal-title":"Curr Genom"},{"key":"3682_CR2","doi-asserted-by":"publisher","first-page":"5730","DOI":"10.3390\/molecules27175730","volume":"27","author":"M Sekhoacha","year":"2022","unstructured":"Sekhoacha M, Riet K, Motloung P, Gumenku L, Adegoke A, Mashele S. Prostate cancer review: genetics, diagnosis, treatment options, and alternative approaches. Molecules. 2022;27:5730.","journal-title":"Molecules"},{"key":"3682_CR3","doi-asserted-by":"publisher","first-page":"T105","DOI":"10.1530\/ERC-13-0545","volume":"21","author":"C Helsen","year":"2014","unstructured":"Helsen C, Van den Broeck T, Voet A, Prekovic S, Van Poppel H, Joniau S, et al. Androgen receptor antagonists for prostate cancer therapy. Endocr Relat Cancer. 2014;21:T105\u201318.","journal-title":"Endocr Relat Cancer"},{"key":"3682_CR4","doi-asserted-by":"publisher","first-page":"T179","DOI":"10.1530\/ERC-16-0422","volume":"23","author":"I Coutinho","year":"2016","unstructured":"Coutinho I, Day TK, Tilley WD, Selth LA. Androgen receptor signaling in castration-resistant prostate cancer: a lesson in persistence. Endocr Relat Cancer. 2016;23:T179\u201397.","journal-title":"Endocr Relat Cancer"},{"key":"3682_CR5","doi-asserted-by":"publisher","first-page":"4588","DOI":"10.1038\/onc.2011.591","volume":"31","author":"DA Dart","year":"2012","unstructured":"Dart DA, Brooke GN, Sita-Lumsden A, Waxman J, Bevan CL. Reducing prohibitin increases histone acetylation, and promotes androgen independence in prostate tumours by increasing androgen receptor activation by adrenal androgens. Oncogene. 2012;31:4588\u201398.","journal-title":"Oncogene"},{"key":"3682_CR6","doi-asserted-by":"publisher","first-page":"7976","DOI":"10.1158\/0008-5472.CAN-04-4076","volume":"65","author":"HJ Zhou","year":"2005","unstructured":"Zhou HJ, Yan J, Luo W, Ayala G, Lin SH, Erdem H, et al. SRC-3 is required for prostate cancer cell proliferation and survival. Cancer Res. 2005;65:7976\u201383.","journal-title":"Cancer Res"},{"key":"3682_CR7","doi-asserted-by":"publisher","first-page":"8112","DOI":"10.1093\/nar\/gkw472","volume":"44","author":"S Sun","year":"2016","unstructured":"Sun S, Zhong X, Wang C, Sun H, Wang S, Zhou T, et al. BAP18 coactivates androgen receptor action and promotes prostate cancer progression. Nucleic Acids Res. 2016;44:8112\u201328.","journal-title":"Nucleic Acids Res"},{"key":"3682_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2407-8-219","volume":"8","author":"A Urbanucci","year":"2008","unstructured":"Urbanucci A, Waltering KK, Suikki HE, Helenius MA, Visakorpi T. Androgen regulation of the androgen receptor coregulators. BMC Cancer. 2008;8:219.","journal-title":"BMC Cancer"},{"key":"3682_CR9","doi-asserted-by":"publisher","first-page":"1757","DOI":"10.1038\/sj.onc.1209967","volume":"26","author":"SC Gamble","year":"2007","unstructured":"Gamble SC, Chotai D, Odontiadis M, Dart DA, Brooke GN, Powell SM, et al. Prohibitin, a protein downregulated by androgens, represses androgen receptor activity. Oncogene. 2007;26:1757\u201368.","journal-title":"Oncogene"},{"key":"3682_CR10","doi-asserted-by":"publisher","first-page":"2996","DOI":"10.1038\/sj.onc.1207444","volume":"23","author":"SC Gamble","year":"2004","unstructured":"Gamble SC, Odontiadis M, Waxman J, Westbrook JA, Dunn MJ, Wait R, et al. Androgens target prohibitin to regulate proliferation of prostate cancer cells. Oncogene. 2004;23:2996\u20133004.","journal-title":"Oncogene"},{"key":"3682_CR11","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1158\/0008-5472.CAN-10-0874","volume":"71","author":"GN Brooke","year":"2011","unstructured":"Brooke GN, Culley RL, Dart DA, Mann DJ, Gaughan L, McCracken SR, et al. FUS\/TLS is a novel mediator of androgen-dependent cell-cycle progression and prostate cancer growth. Cancer Res. 2011;71:914\u201324.","journal-title":"Cancer Res"},{"key":"3682_CR12","doi-asserted-by":"crossref","unstructured":"Chen L, Zhang JJ, Chen Q, Ge WL, Meng LD, Huang XM, et al. Long noncoding RNA SOX2OT promotes the proliferation of pancreatic cancer by binding to FUS. Int J Cancer. 2020;147:175\u201388.","DOI":"10.1002\/ijc.32827"},{"key":"3682_CR13","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1002\/gcc.20858","volume":"50","author":"JI Spitzer","year":"2011","unstructured":"Spitzer JI, Ugras S, Runge S, Decarolis P, Antonescu C, Tuschl T, et al. mRNA and protein levels of FUS, EWSR1, and TAF15 are upregulated in liposarcoma. Genes Chromosomes Cancer. 2011;50:338\u201347.","journal-title":"Genes Chromosomes Cancer"},{"key":"3682_CR14","first-page":"1791","volume":"16","author":"D Xiong","year":"2018","unstructured":"Xiong D, Wu YB, Jin C, Li JJ, Gu J, Liao YF, et al. Elevated FUS\/TLS expression is negatively associated with E-cadherin expression and prognosis of patients with non-small cell lung cancer. Oncol Lett. 2018;16:1791\u20131800.","journal-title":"Oncol Lett"},{"key":"3682_CR15","doi-asserted-by":"publisher","first-page":"175909141454447","DOI":"10.1177\/1759091414544472","volume":"6","author":"RR Sama","year":"2014","unstructured":"Sama RR, Ward CL, Bosco DA. Functions of FUS\/TLS from DNA repair to stress response: implications for ALS. ASN Neuro. 2014;6:1759091414544472.","journal-title":"ASN Neuro"},{"key":"3682_CR16","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1038\/nature06992","volume":"454","author":"X Wang","year":"2008","unstructured":"Wang X, Arai S, Song X, Reichart D, Du K, Pascual G, et al. Induced ncRNAs allosterically modify RNA-binding proteins in cis to inhibit transcription. Nature. 2008;454:126\u201330.","journal-title":"Nature"},{"key":"3682_CR17","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1210\/mend.12.1.0043","volume":"12","author":"CA Powers","year":"1998","unstructured":"Powers CA, Mathur M, Raaka BM, Ron D, Samuels HH. TLS (translocated-in-liposarcoma) is a high-affinity interactor for steroid, thyroid hormone, and retinoid receptors. Mol Endocrinol. 1998;12:4\u201318.","journal-title":"Mol Endocrinol"},{"key":"3682_CR18","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.celrep.2013.01.010","volume":"3","author":"H Mohammed","year":"2013","unstructured":"Mohammed H, D\u2019Santos C, Serandour AA, Ali HR, Brown GD, Atkins A, et al. Endogenous purification reveals GREB1 as a key estrogen receptor regulatory factor. Cell Rep. 2013;3:342\u20139.","journal-title":"Cell Rep"},{"key":"3682_CR19","doi-asserted-by":"publisher","first-page":"e24197","DOI":"10.1371\/journal.pone.0024197","volume":"6","author":"S Haile","year":"2011","unstructured":"Haile S, Lal A, Myung JK, Sadar MD. FUS\/TLS is a co-activator of androgen receptor in prostate cancer cells. PLoS ONE. 2011;6:e24197.","journal-title":"PLoS ONE"},{"key":"3682_CR20","doi-asserted-by":"publisher","first-page":"4094","DOI":"10.1093\/emboj\/cdf412","volume":"21","author":"B Belandia","year":"2002","unstructured":"Belandia B, Orford RL, Hurst HC, Parker MG. Targeting of SWI\/SNF chromatin remodelling complexes to estrogen-responsive genes. EMBO J. 2002;21:4094\u2013103.","journal-title":"EMBO J"},{"key":"3682_CR21","doi-asserted-by":"publisher","first-page":"12298","DOI":"10.1074\/jbc.275.16.12298","volume":"275","author":"G Verrijdt","year":"2000","unstructured":"Verrijdt G, Schoenmakers E, Haelens A, Peeters B, Verhoeven G, Rombauts W, et al. Change of specificity mutations in androgen-selective enhancers evidence for a role of differential DNA binding by the androgen receptor. J Biol Chem. 2000;275:12298\u2013305.","journal-title":"J Biol Chem"},{"key":"3682_CR22","doi-asserted-by":"publisher","first-page":"307","DOI":"10.1016\/0022-4731(89)90098-8","volume":"34","author":"AO Brinkmann","year":"1989","unstructured":"Brinkmann AO, Faber PW, van Rooij HC, Kuiper GG, Ris C, Klaassen P, et al. The human androgen receptor: domain structure, genomic organization and regulation of expression. J Steroid Biochem. 1989;34:307\u201310.","journal-title":"J Steroid Biochem"},{"key":"3682_CR23","doi-asserted-by":"publisher","first-page":"8383","DOI":"10.1128\/MCB.19.12.8383","volume":"19","author":"CL Bevan","year":"1999","unstructured":"Bevan CL, Hoare S, Claessens F, Heery DM, Parker MG. The AF1 and AF2 domains of the androgen receptor interact with distinct regions of SRC1. Mol Cell Biol. 1999;19:8383\u201392.","journal-title":"Mol Cell Biol"},{"key":"3682_CR24","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1042\/BJ20082097","volume":"418","author":"IV Klevernic","year":"2009","unstructured":"Klevernic IV, Morton S, Davis RJ, Cohen P. Phosphorylation of Ewing\u2019s sarcoma protein (EWS) and EWS-Fli1 in response to DNA damage. Biochem J. 2009;418:625\u201334.","journal-title":"Biochem J"},{"key":"3682_CR25","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/0303-7207(94)90096-5","volume":"102","author":"E Kalkhoven","year":"1994","unstructured":"Kalkhoven E, Kwakkenbos-Isbrucker L, de Laat SW, van der Saag PT, van der Burg B. Synthetic progestins induce proliferation of breast tumor cell lines via the progesterone or estrogen receptor. Mol Cell Endocrinol. 1994;102:45\u201352.","journal-title":"Mol Cell Endocrinol"},{"key":"3682_CR26","doi-asserted-by":"publisher","first-page":"15645","DOI":"10.1074\/jbc.M313906200","volume":"279","author":"M Christian","year":"2004","unstructured":"Christian M, Tullet JM, Parker MG. Characterization of four autonomous repression domains in the corepressor receptor interacting protein 140. J Biol Chem. 2004;279:15645\u201351.","journal-title":"J Biol Chem"},{"key":"3682_CR27","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1038\/sj.onc.1210955","volume":"27","author":"GN Brooke","year":"2008","unstructured":"Brooke GN, Parker MG, Bevan CL. Mechanisms of androgen receptor activation in advanced prostate cancer: differential co-activator recruitment and gene expression. Oncogene. 2008;27:2941\u201350.","journal-title":"Oncogene"},{"key":"3682_CR28","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.1128\/MCB.25.4.1425-1436.2005","volume":"25","author":"B Belandia","year":"2005","unstructured":"Belandia B, Powell SM, Garcia-Pedrero JM, Walker MM, Bevan CL, Parker MG. Hey1, a mediator of notch signaling, is an androgen receptor corepressor. Mol Cell Biol. 2005;25:1425\u201336.","journal-title":"Mol Cell Biol"},{"key":"3682_CR29","doi-asserted-by":"publisher","first-page":"6322","DOI":"10.1038\/sj.onc.1203032","volume":"18","author":"H Peterziel","year":"1999","unstructured":"Peterziel H, Mink S, Schonert A, Becker M, Klocker H, Cato AC. Rapid signalling by androgen receptor in prostate cancer cells. Oncogene. 1999;18:6322\u20139.","journal-title":"Oncogene"},{"key":"3682_CR30","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1210\/me.2012-1056","volume":"26","author":"V Reebye","year":"2012","unstructured":"Reebye V, Cano LQ, Lavery DN, Brooke GN, Powell SM, Chotai D, et al. Role of the HSP90-Associated Cochaperone p23 in Enhancing Activity of the Androgen Receptor and Significance for Prostate Cancer. Mol Endocrinol. 2012;26:1694\u2013706.","journal-title":"Mol Endocrinol"},{"key":"3682_CR31","doi-asserted-by":"publisher","first-page":"W755","DOI":"10.1093\/nar\/gkq405","volume":"38","author":"D Emig","year":"2010","unstructured":"Emig D, Salomonis N, Baumbach J, Lengauer T, Conklin BR, Albrecht M. AltAnalyze and DomainGraph: analyzing and visualizing exon expression data. Nucleic Acids Res. 2010;38:W755\u201362.","journal-title":"Nucleic Acids Res"},{"key":"3682_CR32","doi-asserted-by":"publisher","first-page":"W216","DOI":"10.1093\/nar\/gkac194","volume":"50","author":"BT Sherman","year":"2022","unstructured":"Sherman BT, Hao M, Qiu J, Jiao X, Baseler MW, Lane HC, et al. DAVID: a web server for functional enrichment analysis and functional annotation of gene lists (2021 update). Nucleic Acids Res. 2022;50:W216\u201321.","journal-title":"Nucleic Acids Res"},{"key":"3682_CR33","doi-asserted-by":"publisher","first-page":"e1004102","DOI":"10.1371\/journal.pgen.1004102","volume":"10","author":"DJ Hazelett","year":"2014","unstructured":"Hazelett DJ, Rhie SK, Gaddis M, Yan C, Lakeland DL, Coetzee SG, et al. Comprehensive functional annotation of 77 prostate cancer risk loci. PLoS Genet. 2014;10:e1004102.","journal-title":"PLoS Genet"},{"key":"3682_CR34","doi-asserted-by":"publisher","first-page":"2797","DOI":"10.1002\/1878-0261.70065","volume":"19","author":"DA Leach","year":"2025","unstructured":"Leach DA, Chatterjee N, Spahr K, de Almeida GS, Varela-Carver A, Shah TT, et al. Simultaneous inhibition of TRIM24 and TRIM28 sensitises prostate cancer cells to antiandrogen therapy, decreasing VEGF signalling and angiogenesis. Mol Oncol. 2025;19:2797\u2013821.","journal-title":"Mol Oncol"},{"key":"3682_CR35","doi-asserted-by":"publisher","first-page":"D658","DOI":"10.1093\/nar\/gkw983","volume":"45","author":"S Mei","year":"2017","unstructured":"Mei S, Qin Q, Wu Q, Sun H, Zheng R, Zang C, et al. Cistrome Data Browser: a data portal for ChIP-Seq and chromatin accessibility data in human and mouse. Nucleic Acids Res. 2017;45:D658\u201362.","journal-title":"Nucleic Acids Res"},{"key":"3682_CR36","doi-asserted-by":"publisher","first-page":"2502","DOI":"10.1038\/nprot.2013.150","volume":"8","author":"S Wang","year":"2013","unstructured":"Wang S, Sun H, Ma J, Zang C, Wang C, Wang J, et al. Target analysis by integration of transcriptome and ChIP-seq data with BETA. Nat Protoc. 2013;8:2502\u201315.","journal-title":"Nat Protoc"},{"key":"3682_CR37","doi-asserted-by":"publisher","first-page":"959","DOI":"10.18632\/oncotarget.1360","volume":"5","author":"GN Brooke","year":"2014","unstructured":"Brooke GN, Powell SM, Lavery DN, Waxman J, Buluwela L, Ali S, et al. Engineered repressors are potent inhibitors of androgen receptor activity. Oncotarget. 2014;5:959\u201369.","journal-title":"Oncotarget"},{"key":"3682_CR38","doi-asserted-by":"publisher","first-page":"17796","DOI":"10.1074\/jbc.M110.198655","volume":"286","author":"DN Lavery","year":"2011","unstructured":"Lavery DN, Villaronga MA, Walker MM, Patel A, Belandia B, Bevan CL. Repression of androgen receptor activity by HEYL, a third member of the Hairy\/Enhancer-of-split-related family of Notch effectors. J Biol Chem. 2011;286:17796\u2013808.","journal-title":"J Biol Chem"},{"key":"3682_CR39","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-018-03573-6","volume":"9","author":"L Latonen","year":"2018","unstructured":"Latonen L, Afyounian E, Jylha A, Nattinen J, Aapola U, Annala M, et al. Integrative proteomics in prostate cancer uncovers robustness against genomic and transcriptomic aberrations during disease progression. Nat Commun. 2018;9:1176.","journal-title":"Nat Commun"},{"key":"3682_CR40","doi-asserted-by":"publisher","first-page":"4026","DOI":"10.1158\/0008-5472.CAN-15-0217","volume":"75","author":"A Ylipaa","year":"2015","unstructured":"Ylipaa A, Kivinummi K, Kohvakka A, Annala M, Latonen L, Scaravilli M, et al. Transcriptome sequencing reveals PCAT5 as a novel ERG-regulated long noncoding RNA in prostate cancer. Cancer Res. 2015;75:4026\u201331.","journal-title":"Cancer Res"},{"key":"3682_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-24342-y","volume":"12","author":"DA Leach","year":"2021","unstructured":"Leach DA, Mohr A, Giotis ES, Cil E, Isac AM, Yates LL, et al. The antiandrogen enzalutamide downregulates TMPRSS2 and reduces cellular entry of SARS-CoV-2 in human lung cells. Nat Commun. 2021;12:4068.","journal-title":"Nat Commun"},{"key":"3682_CR42","doi-asserted-by":"publisher","first-page":"1921","DOI":"10.1210\/mend-5-12-1921","volume":"5","author":"PH Riegman","year":"1991","unstructured":"Riegman PH, Vlietstra RJ, van der Korput JA, Brinkmann AO, Trapman J. The promoter of the prostate-specific antigen gene contains a functional androgen responsive element. Mol Endocrinol. 1991;5:1921\u201330.","journal-title":"Mol Endocrinol"},{"key":"3682_CR43","doi-asserted-by":"publisher","first-page":"7869","DOI":"10.1073\/pnas.91.17.7869","volume":"91","author":"I Sanchez-Garcia","year":"1994","unstructured":"Sanchez-Garcia I, Rabbitts TH. Transcriptional activation by TAL1 and FUS-CHOP proteins expressed in acute malignancies as a result of chromosomal abnormalities. Proc Natl Acad Sci USA. 1994;91:7869\u201373.","journal-title":"Proc Natl Acad Sci USA"},{"key":"3682_CR44","doi-asserted-by":"publisher","first-page":"2513","DOI":"10.1101\/gad.8.21.2513","volume":"8","author":"H Zinszner","year":"1994","unstructured":"Zinszner H, Albalat R, Ron D. A novel effector domain from the RNA-binding protein TLS or EWS is required for oncogenic transformation by CHOP. Genes Dev. 1994;8:2513\u201326.","journal-title":"Genes Dev"},{"key":"3682_CR45","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/aps.2014.18","volume":"36","author":"MH Tan","year":"2015","unstructured":"Tan MH, Li J, Xu HE, Melcher K, Yong EL. Androgen receptor: structure, role in prostate cancer and drug discovery. Acta Pharm Sin. 2015;36:3\u201323.","journal-title":"Acta Pharm Sin"},{"key":"3682_CR46","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1210\/me.2003-0065","volume":"18","author":"BC Jeong","year":"2004","unstructured":"Jeong BC, Hong CY, Chattopadhyay S, Park JH, Gong EY, Kim HJ, et al. Androgen receptor corepressor-19 kDa (ARR19), a leucine-rich protein that represses the transcriptional activity of androgen receptor through recruitment of histone deacetylase. Mol Endocrinol. 2004;18:13\u201325.","journal-title":"Mol Endocrinol"},{"key":"3682_CR47","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1074\/jbc.M106399200","volume":"277","author":"CE Petre","year":"2002","unstructured":"Petre CE, Wetherill YB, Danielsen M, Knudsen KE. Cyclin D1: mechanism and consequence of androgen receptor co-repressor activity. J Biol Chem. 2002;277:2207\u201315.","journal-title":"J Biol Chem"},{"key":"3682_CR48","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.jsbmb.2004.10.003","volume":"92","author":"Z Culig","year":"2004","unstructured":"Culig Z, Comuzzi B, Steiner H, Bartsch G, Hobisch A. Expression and function of androgen receptor coactivators in prostate cancer. J Steroid Biochem Mol Biol. 2004;92:265\u201371.","journal-title":"J Steroid Biochem Mol Biol"},{"key":"3682_CR49","doi-asserted-by":"publisher","first-page":"D777","DOI":"10.1093\/nar\/gkw1121","volume":"45","author":"SA Forbes","year":"2017","unstructured":"Forbes SA, Beare D, Boutselakis H, Bamford S, Bindal N, Tate J, et al. COSMIC: somatic cancer genetics at high-resolution. Nucleic Acids Res. 2017;45:D777\u2013D783.","journal-title":"Nucleic Acids Res"},{"key":"3682_CR50","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/S1474-4422(24)00517-9","volume":"24","author":"TG Moens","year":"2025","unstructured":"Moens TG, Da Cruz S, Neumann M, Shelkovnikova TA, Shneider NA, Van Den Bosch L. Amyotrophic lateral sclerosis caused by FUS mutations: advances with broad implications. Lancet Neurol. 2025;24:166\u201378.","journal-title":"Lancet Neurol"},{"key":"3682_CR51","doi-asserted-by":"publisher","first-page":"5469","DOI":"10.1158\/0008-5472.CAN-08-0594","volume":"68","author":"SM Dehm","year":"2008","unstructured":"Dehm SM, Schmidt LJ, Heemers HV, Vessella RL, Tindall DJ. Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance. Cancer Res. 2008;68:5469\u201377.","journal-title":"Cancer Res"},{"key":"3682_CR52","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.4161\/cc.21875","volume":"11","author":"AY Tan","year":"2012","unstructured":"Tan AY, Manley JL. TLS\/FUS: a protein in cancer and ALS. Cell Cycle. 2012;11:3349\u201350.","journal-title":"Cell Cycle"},{"key":"3682_CR53","doi-asserted-by":"publisher","first-page":"R147","DOI":"10.1530\/JME-16-0156","volume":"58","author":"J Nautiyal","year":"2017","unstructured":"Nautiyal J. Transcriptional coregulator RIP140: an essential regulator of physiology. J Mol Endocrinol. 2017;58:R147\u2013R158.","journal-title":"J Mol Endocrinol"},{"key":"3682_CR54","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1002\/pros.20170","volume":"63","author":"L Wang","year":"2005","unstructured":"Wang L, Hsu CL, Chang CS. Androgen receptor corepressors: an overview. Prostate. 2005;63:117\u201330.","journal-title":"Prostate"},{"key":"3682_CR55","doi-asserted-by":"publisher","first-page":"1193","DOI":"10.1093\/hmg\/dds526","volume":"22","author":"JG Daigle","year":"2013","unstructured":"Daigle JG, Lanson NA Jr., Smith RB, Casci I, Maltare A, Monaghan J, et al. RNA-binding ability of FUS regulates neurodegeneration, cytoplasmic mislocalization and incorporation into stress granules associated with FUS carrying ALS-linked mutations. Hum Mol Genet. 2013;22:1193\u2013205.","journal-title":"Hum Mol Genet"},{"key":"3682_CR56","doi-asserted-by":"publisher","first-page":"9134","DOI":"10.1039\/D0CC03776A","volume":"56","author":"N Hamad","year":"2020","unstructured":"Hamad N, Watanabe H, Uchihashi T, Kurokawa R, Nagata T, Katahira M. Direct visualization of the conformational change of FUS\/TLS upon binding to promoter-associated non-coding RNA. Chem Commun. 2020;56:9134\u20137.","journal-title":"Chem Commun"},{"key":"3682_CR57","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1373\/clinchem.2011.165977","volume":"57","author":"P Saraon","year":"2011","unstructured":"Saraon P, Jarvi K, Diamandis EP. Molecular alterations during progression of prostate cancer to androgen independence. Clin Chem. 2011;57:1366\u201375.","journal-title":"Clin Chem"},{"key":"3682_CR58","doi-asserted-by":"publisher","first-page":"R112","DOI":"10.1530\/EO-22-0065","volume":"2","author":"DA Leach","year":"2022","unstructured":"Leach DA, Fernandes RC, Bevan CL. Cellular specificity of androgen receptor, coregulators, and pioneer factors in prostate cancer. Endocr Oncol. 2022;2:R112\u201331.","journal-title":"Endocr Oncol"},{"key":"3682_CR59","doi-asserted-by":"publisher","first-page":"898","DOI":"10.3390\/cells11050898","volume":"11","author":"D Ozturan","year":"2022","unstructured":"Ozturan D, Morova T, Lack NA. Androgen receptor-mediated transcription in prostate cancer. Cells. 2022;11:898.","journal-title":"Cells"},{"key":"3682_CR60","doi-asserted-by":"publisher","first-page":"790","DOI":"10.1038\/s41588-020-0664-8","volume":"52","author":"MM Pomerantz","year":"2020","unstructured":"Pomerantz MM, Qiu X, Zhu Y, Takeda DY, Pan W, Baca SC, et al. Prostate cancer reactivates developmental epigenomic programs during metastatic progression. Nat Genet. 2020;52:790\u20139.","journal-title":"Nat Genet"},{"key":"3682_CR61","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1016\/j.celrep.2016.10.001","volume":"17","author":"V Kedage","year":"2016","unstructured":"Kedage V, Selvaraj N, Nicholas TR, Budka JA, Plotnik JP, Jerde TJ, et al. An Interaction with Ewing\u2019s Sarcoma Breakpoint Protein EWS Defines a Specific Oncogenic Mechanism of ETS Factors Rearranged in Prostate Cancer. Cell Rep. 2016;17:1289\u2013301.","journal-title":"Cell Rep"},{"key":"3682_CR62","doi-asserted-by":"publisher","first-page":"4646","DOI":"10.1038\/onc.2012.490","volume":"32","author":"M Ballarino","year":"2013","unstructured":"Ballarino M, Jobert L, Dembele D, de la Grange P, Auboeuf D, Tora L. TAF15 is important for cellular proliferation and regulates the expression of a subset of cell cycle genes through miRNAs. Oncogene. 2013;32:4646\u201355.","journal-title":"Oncogene"},{"key":"3682_CR63","first-page":"2690","volume":"61","author":"KL Rossow","year":"2001","unstructured":"Rossow KL, Janknecht R. The Ewing\u2019s sarcoma gene product functions as a transcriptional activator. Cancer Res. 2001;61:2690\u20135.","journal-title":"Cancer Res"},{"key":"3682_CR64","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-31959-0","volume":"13","author":"L Tang","year":"2023","unstructured":"Tang L, Guo C, Li X, Zhang B, Huang L. TAF15 promotes cell proliferation, migration and invasion of gastric cancer via activation of the RAF1\/MEK\/ERK signalling pathway. Sci Rep. 2023;13:5846.","journal-title":"Sci Rep"},{"key":"3682_CR65","volume":"6","author":"E Aikio","year":"2023","unstructured":"Aikio E, Koivukoski S, Kallio E, Sadeesh N, Niskanen EA, Latonen L. Complementary analysis of proteome-wide proteomics reveals changes in RNA binding protein-profiles during prostate cancer progression. Cancer Rep. 2023;6:e1886.","journal-title":"Cancer Rep"}],"container-title":["Oncogene"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03682-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03682-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03682-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,10]],"date-time":"2026-03-10T11:03:31Z","timestamp":1773140611000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41388-026-03682-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,6]]},"references-count":65,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,3,10]]}},"alternative-id":["3682"],"URL":"https:\/\/doi.org\/10.1038\/s41388-026-03682-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.3.rs-6609773\/v1","asserted-by":"object"}]},"ISSN":["0950-9232","1476-5594"],"issn-type":[{"value":"0950-9232","type":"print"},{"value":"1476-5594","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,6]]},"assertion":[{"value":"7 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 December 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 January 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 February 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 March 2026","order":6,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":7,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"In this article funding number 'RIA17-ST2-017' in the Funding information section was incorrectly given as 'RIA17-ST2-017'.","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Approval for the use of patient samples was granted by the ethical committee of the Tampere University Hospital and the National Authority for Medicolegal Affairs and all samples were collected with informed consent. All methods were performed in accordance with the relevant guidelines and regulations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}]}}